About Humanwell Healthcare (Group) Co., Ltd.
Humanwell Healthcare (Group) is a pharmaceutical group headquartered in Wuhan, Hubei Province, founded in 1993 and listed in Shanghai. Its official English website presents it as an integrated provider of pharmaceutical products and services, with more than 2,000 R&D personnel, hundreds of products in development and exports to around seventy countries and regions.
Its strategic areas are anaesthesia and analgesia, central nervous system diseases and reproductive health, supported by specialised subsidiaries such as Yichang Humanwell, described as the first Chinese oral solid dosage factory in its segment certified by the US FDA and UK MHRA, and by strong soft-capsule capacity through its Wuhan operation and PuraCap in the United States.
The group has built an international presence unusual among Chinese pharmaceutical companies, with manufacturing and commercial subsidiaries in the United States (Epic Pharma), Germany (Paion), Mali and Ethiopia, and dozens of ANDA approvals in the US market. Its profile combines domestic leadership in controlled medicines with an overseas manufacturing and registration platform.
Its strategic areas are anaesthesia and analgesia, central nervous system diseases and reproductive health, supported by specialised subsidiaries such as Yichang Humanwell, described as the first Chinese oral solid dosage factory in its segment certified by the US FDA and UK MHRA, and by strong soft-capsule capacity through its Wuhan operation and PuraCap in the United States.
The group has built an international presence unusual among Chinese pharmaceutical companies, with manufacturing and commercial subsidiaries in the United States (Epic Pharma), Germany (Paion), Mali and Ethiopia, and dozens of ANDA approvals in the US market. Its profile combines domestic leadership in controlled medicines with an overseas manufacturing and registration platform.